Scientists at Israel’s Weizmann and Technion Institutes have found that each melanoma patient has a different profile of neo-antigens (mutated peptides) on their tumors. Doctors can then extract and grow the T-cells best suited to target the neo-antigens on both primary and secondary cancers.
Breakthrough melanoma treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.